Pathophysiology of Dyslipidemia and its Management by PCSK9 Inhibitors: A Literature Review

Abstract

Dyslipidemia is a disease of abnormal lipid levels in the blood that contributes to the atherosclerotic process. This atherogenic process leads to the formation of plaque and also leads to thromboembolic events and other vascular accidents. It is known that high-density lipoprotein cholesterol serves as a protective effect on the vessel wall and causes the reduction in the progression of atherosclerosis. And multiple interventions are directed in maintaining a higher level of the aforementioned lipoprotein cholesterol. While the low-density lipoprotein stays controversial but lowering its levels through various therapeutic agents is the main goal in the management of dyslipidemia. A newer group of drugs, PCSK9 inhibitors lowers the levels of low-density lipoprotein through modulating PCKS9 gene involved in cholesterol metabolism and affects the levels of the lipoproteins by controlling the receptors. The inhibitors of this gene decrease PCSK9-induced low-density lipoprotein receptor degradation in the lysosomes of hepatocytes increasing its recycling and expression on the cell surface, causing increased clearance of low-density lipoprotein from the circulation. These drugs Alicuromab, Evolocumab and along with other agents can be a novel approach in controlling dyslipidemic state. This review revisits the literature in understanding the pathophysiology of dyslipidemia along with its management by PCKS9 inhibitors, its mechanism of action, its pharmacokinetics, the results of the clinical trials and the limitations in its application.

Pengaruh Suplementasi Tepung Daun Kelor Terhadap Kadar HDL Dan Trigliserida Tikus Sprague Dawley Dislipidemia

“…18 Asupan kolesterol dan asam lemak yang tinggi menyebabkan kolesterol dalam darah meningkat. 19,20 Kolesterol yang diserap dari usus diangkut oleh kilomikron yang terbentuk dalam mukosa. Kilomikron mengangkut trigliserida ke jaringan adiposa serta jaringan intrahepatik, dimana bahan baku untuk sintesis kolesterol di hati (jalur eksogen) adalah lemak dan karbohidrat atau protein yang dikonsumsi.…”